These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 838406)

  • 1. Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible?
    Iser JH; Murphy GM; Dowling RH
    Gut; 1977 Jan; 18(1):7-15. PubMed ID: 838406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation.
    Podda M; Zuin M; Dioguardi ML; Festorazzi S; Dioguardi N
    Hepatology; 1982; 2(3):334-9. PubMed ID: 7076116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.
    Iser JH; Maton PN; Murphy GM; Dowling RH
    Br Med J; 1978 Jun; 1(6126):1509-12. PubMed ID: 656777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of obesity and weight reduction on biliary cholesterol saturation and the response to chenodeoxycholic acid.
    Reuben A; Qureshi Y; Murphy GM; Dowling RH
    Eur J Clin Invest; 1986 Apr; 16(2):133-42. PubMed ID: 3089808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
    Maton PN; Murphy GM; Dowling RH
    Gut; 1980 Dec; 21(12):1082-6. PubMed ID: 7461467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cholesterol saturation of bile and its reduction by chenodeoxycholic acid in massively obese patients.
    Whiting MJ; Hall JC; Iannos J; Roberts HG; Watts JM
    Int J Obes; 1984; 8(6):681-8. PubMed ID: 6533091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary lipid output during three meals and an overnight fast. II. Effect of chenodeoxycholic acid treatment in gallstone subjects.
    Northfield TC; LaRusso NF; Hofmann AF; Thistle JL
    Gut; 1975 Jan; 16(1):12-7. PubMed ID: 1140620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS).
    Grundy SM; Lan SP; Lachin J
    J Clin Invest; 1984 Apr; 73(4):1156-66. PubMed ID: 6368591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral chenodeoxycholic acid on bile acid kinetics and biliary lipid composition in women with cholelithiasis.
    Danzinger RC; Hofmann AF; Thistle JL; Schoenfield LJ
    J Clin Invest; 1973 Nov; 52(11):2809-21. PubMed ID: 4583981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chenotherapy for gallstone dissolution. II. Induced changes in bile composition and gallstone response.
    Hofmann AF; Thistle JL; Klein PD; Szczepanik PA; Yu PY
    JAMA; 1978 Mar; 239(12):1138-44. PubMed ID: 628065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism.
    Adler RD; Bennion LJ; Duane WC; Grundy SM
    Gastroenterology; 1975 Feb; 68(2):326-34. PubMed ID: 1116678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption.
    Ponz de Leon M; Carulli N; Loria P; Iori R; Zironi F
    Gastroenterology; 1979 Aug; 77(2):223-30. PubMed ID: 447035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
    Carulli N; Ponz De Leon M; Zironi F; Pinetti A; Smerieri A; Iori R; Loria P
    J Lipid Res; 1980 Jan; 21(1):35-43. PubMed ID: 7354253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of litholytic bile acids on cholesterol absorption in gallstone patients.
    LaRusso NF; Thistle JL
    Gastroenterology; 1983 Feb; 84(2):265-71. PubMed ID: 6848406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desaturation of bile and cholesterol gallstone dissolution with chenodeoxycholic acid.
    Hofmann AF
    Am J Clin Nutr; 1977 Jun; 30(6):993-1000. PubMed ID: 326024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of low-dose and intermittent chenodeoxycholic acid therapy of gallstones.
    Marks JW; Bonorris GG; Chung A; Coyne MJ; Okun R; Lachin JM; Schoenfield LJ
    Am J Dig Dis; 1977 Oct; 22(10):856-60. PubMed ID: 920688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence.
    Maton PN; Iser JH; Reuben A; Saxton HM; Murphy GM; Dowling RH
    Medicine (Baltimore); 1982 Mar; 61(2):86-97. PubMed ID: 7062856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of varying doses of chenodeoxycholic acid on bile lipid and biliary bile acid composition in gallstone patients: a dose-response study.
    Thistle JL; Hofmann AF; Yu PY; Ott B
    Am J Dig Dis; 1977 Jan; 22(1):1-6. PubMed ID: 835542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings: Is intermittent chenodeoxycholic acid therapy feasible for dissolving gallstones? The speed of change in biliary lipids and bile acids after starting and stopping treatment.
    Iser JH; Murphy GM; Dowling RH
    Gut; 1975 Oct; 16(10):840. PubMed ID: 1205324
    [No Abstract]   [Full Text] [Related]  

  • 20. Biliary lipid metabolism in gallstone disease and during gallstone dissolution treatment.
    Nilsell K
    Acta Chir Scand Suppl; 1985; 528():1-38. PubMed ID: 3866449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.